Publications by authors named "Maria Cosenza"

Claim this Profile
L
Liquid L-T4 therapy in hypothyroid patients with gastric diseases, an observational study.
Poupak Fallahi, Francesca Ragusa, Armando Patrizio, Valeria Mazzi, Chiara Botrini, Maria Carla Cosenza

Front Endocrinol (Lausanne)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment.
Maria Cosenza, Stefano Sacchi, Samantha Pozzi

Int J Mol Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination.
Maria Cosenza, Monica Civallero, Luigi Marcheselli, Stefano Sacchi, Samantha Pozzi

Apoptosis· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Maria Cosenza, Samantha Pozzi

Int J Mol Sci· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-Penetrating CaCO₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma.
Viviana Vergaro, Monica Civallero, Cinzia Citti, Maria Cosenza, Francesca Baldassarre

Cancers (Basel)· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.
Monica Civallero, Maria Cosenza, Samantha Pozzi, Stefano Sacchi

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
Maria Cosenza, Monica Civallero, Luigi Marcheselli, Stefano Sacchi, Samantha Pozzi

Apoptosis· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.
Maria Cosenza, Monica Civallero, Stefania Fiorcari, Samantha Pozzi, Luigi Marcheselli

Cancer Biol Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of BKM120 and BEZ235 against Lymphoma Cells.
Monica Civallero, Maria Cosenza, Samantha Pozzi, Alessia Bari, Paola Ferri

Biomed Res Int· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Maria Cosenza, Monica Civallero, Samantha Pozzi, Luigi Marcheselli, Alessia Bari

Hematol Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.
Monica Civallero, Maria Cosenza, Luigi Marcheselli, Samantha Pozzi, Stefano Sacchi

Expert Opin Investig Drugs· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.
Maria Cosenza, Monica Civallero, Giulia Grisendi, Luigi Marcheselli, Erika Roat

Ann Hematol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic profiling of enzastaurin-treated B cell lymphoma RL cells.
Monica Civallero, Maria Cosenza, Antonino Neri, Alessia Bari

Hematol Oncol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
Monica Civallero, Maria Cosenza, Alessia Bari, Stefano Sacchi

Expert Opin Investig Drugs· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.
Monica Civallero, Maria Cosenza, Giulia Grisendi, Luigi Marcheselli, Katia Todoerti

Leuk Lymphoma· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
Donata Verdelli, Lucia Nobili, Katia Todoerti, Daniela Intini, Maria Cosenza

Hematol Oncol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
Antonino Neri, Sandra Marmiroli, Pierfrancesco Tassone, Luigia Lombardi, Lucia Nobili, Maria Cosenza

Leuk Lymphoma· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.
Maria Cosenza, Monica Civallero, Stefano Sacchi, Raffaella Marcheselli, Samantha Pozzi

Leuk Lymphoma· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis